Literature DB >> 16170374

The c-Src tyrosine kinase associates with the catalytic domain of ErbB-2: implications for ErbB-2 mediated signaling and transformation.

Harold Kim1, Richard Chan, David L Dankort, Dongmei Zuo, Monica Najoukas, Morag Park, William J Muller.   

Abstract

c-Src associates with and is activated by the ErbB-2 receptor tyrosine kinase, but is unable to bind the EGFR. Although c-Src has been found to interact directly and specifically with the ErbB-2 receptor, the significance of this interaction is unclear. Using both chimeric receptor and site-directed mutagenesis approaches, the region of interaction of c-Src on ErbB-2 was identified. Significantly, EGFR could be converted into a receptor capable of binding c-Src by replacement of a catalytic domain of ErbB-2. We further demonstrated that MDCK cells that express mutant EGFR that are competent in c-Src recruitment lose epithelial polarity in organoid cultures, whereas cells overexpressing the wild-type EGFR retain a polarized phenotype. ErbB-2-dependent activation of c-Src results in disruption of epithelial cell-cell contacts leading to cell dispersal that correlates with the re-localization of phospho-MAPK to focal adhesions. Taken together, these observations suggest that recruitment of c-Src to these closely related EGFR family members plays a critical role in modulating cell polarity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16170374     DOI: 10.1038/sj.onc.1208898

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  33 in total

1.  Cigarette smoke induces aberrant EGF receptor activation that mediates lung cancer development and resistance to tyrosine kinase inhibitors.

Authors:  Simone Filosto; Cathleen R Becker; Tzipora Goldkorn
Journal:  Mol Cancer Ther       Date:  2012-02-01       Impact factor: 6.261

Review 2.  Lung injury and lung cancer caused by cigarette smoke-induced oxidative stress: Molecular mechanisms and therapeutic opportunities involving the ceramide-generating machinery and epidermal growth factor receptor.

Authors:  Tzipora Goldkorn; Simone Filosto; Samuel Chung
Journal:  Antioxid Redox Signal       Date:  2014-07-01       Impact factor: 8.401

3.  Loss of Hsp90 association up-regulates Src-dependent ErbB2 activity.

Authors:  Wanping Xu; Xitong Yuan; Kristin Beebe; Zhexin Xiang; Len Neckers
Journal:  Mol Cell Biol       Date:  2006-10-09       Impact factor: 4.272

Review 4.  Signal transduction in transgenic mouse models of human breast cancer--implications for human breast cancer.

Authors:  Richard Marcotte; William J Muller
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-07-24       Impact factor: 2.673

5.  The prognostic role of phospho-Src family kinase analysis in tongue cancer.

Authors:  Ofer Ben-Izhak; Victoria Cohen-Kaplan; Rafael M Nagler
Journal:  J Cancer Res Clin Oncol       Date:  2010-01       Impact factor: 4.553

6.  Schizophrenia susceptibility pathway neuregulin 1-ErbB4 suppresses Src upregulation of NMDA receptors.

Authors:  Graham M Pitcher; Lorraine V Kalia; David Ng; Nathalie M Goodfellow; Kathleen T Yee; Evelyn K Lambe; Michael W Salter
Journal:  Nat Med       Date:  2011-03-27       Impact factor: 53.440

Review 7.  The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis.

Authors:  M M Moasser
Journal:  Oncogene       Date:  2007-04-30       Impact factor: 9.867

8.  Distinct effects of the mesenchymal dysplasia gene variant of murine Patched-1 protein on canonical and non-canonical Hedgehog signaling pathways.

Authors:  Malcolm C Harvey; Andrew Fleet; Nadia Okolowsky; Paul A Hamel
Journal:  J Biol Chem       Date:  2014-02-25       Impact factor: 5.157

Review 9.  Neuregulin-ERBB signaling in the nervous system and neuropsychiatric diseases.

Authors:  Lin Mei; Klaus-Armin Nave
Journal:  Neuron       Date:  2014-07-02       Impact factor: 17.173

10.  The role of cooperativity with Src in oncogenic transformation mediated by non-small cell lung cancer-associated EGF receptor mutants.

Authors:  B M Chung; M Dimri; M George; A L Reddi; G Chen; V Band; H Band
Journal:  Oncogene       Date:  2009-03-23       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.